Glaukos Corporation

Glaukos is the company behind iDose TR, an FDA-approved treatment for reducing intraocular pressure in people with open-angle glaucoma or ocular hypertension. The product is a travoprost intracameral implant designed to provide continuous, long-term prostaglandin analog therapy directly in the anterior chamber. Glaukos presents iDose TR as an interventional glaucoma option that may reduce reliance on pressure-lowering eye drops and the challenges associated with their ongoing use.

The company’s website offers healthcare professionals product information, prescribing details, efficacy and safety resources, and billing and coding materials. It also provides options to request information from a representative and sign up for product updates. iDose TR is administered into the eye under standard aseptic conditions by a healthcare professional.

Its use is subject to important contraindications and precautions, including certain eye infections, corneal conditions, and hypersensitivity to its ingredients; patients should be monitored as directed. Glaukos encourages reporting side effects and provides access to full prescribing information so clinicians can review appropriate use and safety considerations